Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494963 | 1.00 | KDM4A (0.43) | KDM4ALMNATSHRNAAAPOLB | |
| SCHEMBL5495851 | 0.82 | KDM4A (0.43) | KDM4ALMNANAAAPOLBCNR1 | |
| SCHEMBL5501526 | 0.81 | KDM4A (0.44) | KDM4ALMNANAAAPOLBCNR1 | |
| SCHEMBL6443393 | 0.78 | CTSK (0.43) | KDM4APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL988168 | 0.78 | NAAA (0.59) | KDM4ALMNANAAAPOLBCYP3A4 | |
| SCHEMBL5498907 | 0.77 | LMNA (0.43) | KDM4ALMNATSHRCYP3A4CYP2D6 | |
| SCHEMBL6443377 | 0.76 | CTSK (0.55) | — | |
| SCHEMBL985564 | 0.76 | ASAH1 (0.54) | KDM4ALMNATSHRNAAAPOLB | |
| SCHEMBL5491147 | 0.75 | CHRNB2 (0.59) | — | |
| SCHEMBL5496714 | 0.75 | CHRNB2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753782-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |